956P - The role of miR-155 in the apoptosis of human lymphoma cell induced by CIK cells

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Basic Science
Lymphomas
Translational Research
Presenter Liu Miao
Citation Annals of Oncology (2014) 25 (suppl_4): iv327-iv339. 10.1093/annonc/mdu339
Authors L. Miao1, T. Rong2, J. Yi1
  • 1Dept Of Paediatrics, Wuhan Univ, Renmin Hospital, hospital, 430060 - Wuhan/CN
  • 2Dept Of Paediatrics, Wuhan Univ, Renmin Hospital, hospital, 430060 - Wuan/CN

Abstract

Aim

To observe the effect of cytokine-induced killer cells (CIK) on the apoptosis of human lymphoma cells (Raji and BJAB), and explore the role of microRNA-155(miR-155) in this process.

Methods

MiR-155 was determined by real-time quantitative PCR, and the apoptosis was detected by flow cytometry in Raji and BJAB cells. Psi CHECK2-CEBPB 3′-UTR containing the binding site of miR-155 was constructed, and then transfected into Raji and BJAB cells. Luciferase activity of CEBPB (CCAAT/enhancer binding protein beta) was determined with the assistance of a dual luciferase report system.

Results

CIK cells could promote Raji and BJAB cells apoptosis (t = 3.634, P < 0.05; t = 3.976, P < 0.05), and increase the expression of miR-155 in Raji by (6.87 ± 0.19) fold (t = 2.787, P < 0.05), meanwhile, in BJAB cells by (5.06 ± 0.25) fold (t = 3.513, P < 0.05). Moreover, miR-155 inhibitor might block this process (t = 3.842, P < 0.05; t = 4.016, P < 0.05). Furthermore, miR-155 mimics induced Raji and BJAB cells apoptosis (t = 4.239, P < 0.05; t = 3.477, P < 0.05). MiR-155 targeted at the site of CEBPB 3'-UTR, and CIK cells could decrease the luciferase activity of Raji cells by (42.89 ± 2.06)% (t = 3.281, P < 0.05); meanwhile, in BJAB cells by (37.02 ± 1.98)% (t = 4.933, P < 0.05).

Conclusions

CIK cells could enhance human lymphoma Raji and BJAB cells apoptosis by upregulating miR-155, which may provide a new database to elucidate lymphoma cell therapy using CIK cells.

Disclosure

All authors have declared no conflicts of interest.